Idorsia Ltd.
0RQE.IL
International Order Book5.69
CHF
-0.21
- -
Idorsia Ltd.
0RQE.IL
(International Order Book)
Recent
price
5.69
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Idorsia Ltd. is a biopharmaceutical company focused on innovative prescription medicines for unmet medical needs, with headquarters in Allschwil, Switzerland, founded in 2017 as a spin-off of Actelion and listed on the SIX Swiss Exchange (Ticker: IDIA). The company develops, manufactures, and markets late-stage pharmaceutical therapies across multiple therapeutic areas, including cardiometabolic, central nervous system, immunology, and oncology markets, and pursues global commercialization through direct subsidiaries and strategic partnerships. Main products and services: research and development for novel small molecules and biologics; clinical development services and phase-appropriate translational research; regulatory submissions and global product approvals; manufacturing of clinical and commercial drug substances and finished dosage forms; commercial sales and marketing of approved therapies; life-cycle management, post-approval studies, and pharmacovigilance; collaboration and licensing agreements with biotechnology and pharmaceutical partners; portfolio management across specialty medicines, with a focus on patients with high unmet need; digital health and data-driven insights to support patient access and outcomes. Latest major company changes: enters strategic partnerships and licensing arrangements to expand pipeline and global reach; completes funding announcements and equity transactions to support late-stage development; advances new product candidates into pivotal trials and supports regulatory submissions in key markets; implements organizational restructurings and efficiency programs to optimize operations and cost structures; expands geographic footprint through new market approvals and commercial launches in Europe, the Americas, and Asia-Pacific. Industry and business segments: biopharmaceuticals, specialized medicines, and clinical development services; therapeutic areas include neurology, immunology, metabolic disorders, cardiovascular diseases, and oncology; revenue through product sales, collaboration and licensing revenue, and development funding; focus on rare and high-need conditions; strategic collaborations with global pharmaceutical partners. Geographic operations: operates internationally with commercial activities in Europe, North America, Asia-Pacific, and other regions; maintains manufacturing and development facilities in Switzerland and selected alliance sites; distribution through regional affiliates and distributors to multiple countries. Founding year and headquarters location: founded in 2017 as a spin-off of Actelion; headquartered in Allschwil, Switzerland. Subsidiaries/parent relationships: independent publicly traded company with subsidiaries and regional affiliates supporting research, development, and commercialization; maintains strategic partnerships and licensing agreements with third-party organizations to expand its pipeline and market access.